RMC-4998 formic is an orally active inhibitor targeting the GTP-bound state of the KRASG12C mutant. It forms a trimeric complex with intracellular CYPA and the activated KRASG12C mutant, displaying an IC50 value of 28 nM. This compound inhibits ERK signaling and induces apoptosis in KRASG12C mutant cancer cells and is utilized in tumor research.
Target:
PI3K|||Ras|||Apoptosis|||ERK|||mTOR
* VAT and and shipping costs not included. Errors and price changes excepted
